Detail A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients (from International Journal of Antimicrobial Agents 2016, 47, 184-194) Bibliografi Author: Perez-Pitarch, Alejandro ; Guglieri-Lopez, Beatriz ; Ferriols-Lisart, Rafael ; Merino-Sanjuan, Matilde Topik: Sofosbuvir; Meta-analysis; Hepatitis C virus; Modelling; Simulation; Hepatitis - Drug new Bahasa: (EN )     Penerbit: Elsevier     Tahun Terbit: 2016     Jenis: Article - diterbitkan di jurnal ilmiah internasional Fulltext: 1-s2.0-S0924857916000030.pdf (1.29MB; 0 download) Abstract The objective of this study was to compare the efficacy of sofosbuvir-based treatments in patients withchronic hepatitis C virus (HCV) infection using a model-based meta-analysis (MBMA). A bibliographicsearch was performed to identify clinical trials involving sofosbuvir as a unique direct-acting antiviral(DAA) agent or together with daclatasvir, ledipasvir or simeprevir for the treatment of diagnosed HCVinfection. The time course of the virological response (VR) was modelled to estimate the effect of treat-ment and the influence of population characteristics on the longitudinal efficacy profile. The model wasvalidated and simulations of 10 different treatment schedules were performed. Data from 19 clinical tri-als were included in the analysis. According to the developed model, therapy with sofosbuvir + ledipasviris the most effective therapy in all scenarios, but it does not differ greatly in terms of sustained VRwith respect to other combinations of DAA treatments. In conclusion, this MBMA generates knowledgeregarding hypothetical head-to-head trials that have not been conducted previously. Therapies withsofosbuvir + ledipasvir are probably the most effective sofosbuvir-based treatments. [hepatitis - drug new] Opini Anda Klik untuk menuliskan opini Anda tentang koleksi ini! Lihat Sejarah Pengadaan  Konversi Metadata   Kembali

Copyright © 2006, 2007 Unika Atma Jaya, all rights reserved